PanCAN’s Precision Promise Clinical Trial Consortium sites were selected through a competitive, peer-review process and include premier cancer treatment institutions across the country.
Check back here to see which sites are open and enrolling patients.
Cedars-Sinai Medical Center (Los Angeles, CA) – SITE OPEN
Principal investigator: Andrew Hendifar, MD
Dana-Farber/Harvard Cancer Center (Boston, MA)
Principal investigator: Brian Wolpin, MD, MPH
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington (Seattle, WA) – SITE OPEN
Principal investigator: Andrew Coveler, MD
Johns Hopkins Medicine (Baltimore, MD) – SITE OPEN
Principal Investigator: Daniel Laheru, MD
Memorial Sloan Kettering Cancer Center (New York City, NY) – SITE OPEN
Principal investigator: Eileen O’Reilly, MD
Moores Cancer Center at UC San Diego Health (San Diego, CA) – SITE OPEN
Principal investigator: Aaron Miller, MD
Perelman School of Medicine University of Pennsylvania (Philadelphia, PA) – SITE OPEN
Principal investigator: Gregory Beatty, MD, PhD
Perlmutter Cancer Center/NYU Langone Health (New York City, NY) – SITE OPEN
Principal investigator: Diane Simeone, MD
The University of Chicago (Chicago, IL) – SITE OPEN
Principal investigator: Hedy Kindler, MD
The University of Texas MD Anderson Cancer Center (Houston, TX) – SITE OPEN
Principal Investigator: Shubham Pant, MD
UC San Francisco Helen Diller Family Comprehensive Cancer Center (San Francisco, CA)
Principal investigator: Andrew Ko, MD
University of Florida Health – Cancer Center (Gainesville, FL) – SITE OPEN
Principal investigator: Thomas George, MD, FACP
Virginia Mason Medical Center (Seattle, WA) – SITE OPEN
Principal investigator: Vincent Picozzi, MD
Washington University School of Medicine (St. Louis, MO) – SITE OPEN
Principal investigator: Kian-Huat Lim, MD, PhD
Weill Cornell Medicine (New York City, NY)
Principal investigator: Manuel Hidalgo, MD, PhD
PRECISION PROMISESM is a service mark of Pancreatic Cancer Action Network, Inc.
